Phase 2 Liver Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have signed, or are able to sign, an informed consent form for the study
• People aged 18 to 75 years old at the time of signing the consent form
• People who have been diagnosed with hepatocellular carcinoma (a type of liver cancer) confirmed by a tissue biopsy
• People whose liver cancer was initially able to be surgically removed, but whose tumour had features that put them at higher risk of the cancer coming back — this includes specific combinations of tumour size, number of tumours, whether cancer had spread into nearby blood vessels, and/or poor tumour cell quality (confirm with trial site for your specific situation)
• People who have at least one tumour that can be measured using standard imaging scans
• People whose liver is functioning at a level doctors classify as "Child-Pugh A" (a measure of liver health)
• People whose general physical health and ability to carry out daily activities is rated as 0 or 1 on a standard medical scale (meaning fully active or able to carry out light activity)
• People who have not previously received any local or whole-body treatment for their liver cancer
• People who test negative for HIV at the screening stage

Who may not be able to join:

• People whose liver cancer is a specific less common type, including fibrolamellar, sarcomatoid, mixed cholangiocarcinoma, recurrent, or diffuse liver cancer
• People who have had a clinically diagnosed episode of hepatic encephalopathy (brain problems caused by liver disease) within the past 6 months
• People who have autoimmune hepatitis (a liver condition where the immune system attacks the liver), confirmed by liver biopsy
• People who have previously had an organ transplant
• People who have clinical symptoms of fluid build-up around the lungs, abdomen, or heart, or who have any history of kidney disease or nephrotic syndrome (a kidney disorder)
• People who have taken part in another clinical trial and received an experimental treatment within 28 days before this study would begin
• People who have untreated or incompletely treated enlarged veins in the food pipe or stomach that are bleeding or are considered at high risk of bleeding
• People who have had a bleeding episode from enlarged veins in the food pipe or stomach within the 6 months before the study would begin
• People who are known to have had a severe allergic reaction (such as anaphylaxis) to contrast dye used in medical imaging
• People who are pregnant or currently breastfeeding
• People who are unable to provide informed consent

Important: Always verify eligibility with the trial site directly before applying.